Comparative analysis of clinicopathological correlations of cyclooxygenase-2 expression in resectable pancreatic cancer.
OBJECTIVE
To perform a comparative analysis of clinicopathological correlations of cyclooxygenase-2 (COX-2) expression in pancreatic cancer, examined by monoclonal and polyclonal antibodies.


METHODS
The COX-2 expression in 85 resection specimens of pancreatic ductal adenocarcinoma was immunohistochemically examined using both monoclonal and polyclonal antibodies. The final immunoscores were obtained by multiplying the percentage of positive cells with the numeric score reflecting the staining intensity. COX-2 expression levels were classified into three categories (0, 1+, and 2+) and the clinicopathological correlations were statistically evaluated and analyzed.


RESULTS
The positive tumor expression rates of COX-2 were 80.5% using monoclonal antibody and 69.4% using polyclonal antibody. In the Kaplan-Meier analysis, no significant correlations were found between levels of COX-2 expression and overall survival (OS), but trends to longer OS were found in COX-2 negative cases using monoclonal antibody. Significantly longer disease free survival was revealed in COX-2 negative cases using monoclonal antibody (P = 0.019). No correlations between COX-2 expression levels and grade (G), tumor (T) status and nodal (N) status were demonstrated. Low histological grade showed a strong association with a longer OS (P < 0.001). Correlation of survival and T status revealed a shorter OS in T3 tumors, but the results reached only marginal statistical significance (P = 0.070). In the multivariate Cox proportional hazards regression model, histological grade, T and N status remained valuable predictors of a worse survival with borderline significance for T [hazards ratio (HR) = 4.18 for G (if G = 3, P < 0.001); HR = 1.64 for T (if T = 3, P = 0.065); HR = 2.53 for N (if N = 1, P = 0.006)]. Higher grade, T or N status was associated with a worse OS.


CONCLUSIONS
The immunohistochemically assessed level of COX-2 expression does not seem to represent a valuable independent prognostic factor and is not superior to the conventional prognostic factors.
Hermanova
Marketa
M
First Department of Pathologic Anatomy, Medical Faculty of Masaryk University and St. Anne's University Hospital, Pekarska 53, 65691 Brno, Czech Republic. marketa.hermanova@fnusa.cz
Karasek
Petr
P
Tomasek
Jiri
J
Lenz
Jiri
J
Jarkovsky
Jiri
J
Dite
Petr
P
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000378:metabolism; D051546:Cyclooxygenase 2 / Q000096:biosynthesis*; D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008297:Male; D008875:Middle Aged; D010183:Pancreatic Ducts / Q000201:enzymology / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000201:enzymology* / Q000601:surgery*; D011379:Prognosis; D016016:Proportional Hazards Models
D000911:Antibodies, Monoclonal; D051546:Cyclooxygenase 2
Am J Clin Oncol. 2001 Oct;24(5):447-52
11586094
Pancreas. 2009 Jul;38(5):565-71
19346994
Crit Rev Clin Lab Sci. 2000 Oct;37(5):431-502
11078056
Br J Cancer. 2005 Jun 20;92(12):2225-32
15928668
J Gastroenterol Hepatol. 2002 Aug;17(8):914-21
12164968
Cancer Res. 1997 May 1;57(9):1731-4
9135016
Surg Oncol. 2002 May;10(4):153-69
12020670
Pancreatology. 2007;7(2-3):167-73
17592230
Clin Cancer Res. 1999 Aug;5(8):2018-24
10473081
Am J Pathol. 1993 Aug;143(2):545-54
8342602
Am J Clin Pathol. 2002 Aug;118(2):194-201
12162677
Pancreatology. 2005;5(4-5):361-9
15980665
Anticancer Res. 2000 Jul-Aug;20(4):2625-31
10953335
Am J Pathol. 2000 Jun;156(6):1821-5
10854204
Eur J Gastroenterol Hepatol. 2008 Aug;20(8):732-9
18617777
Curr Gastroenterol Rep. 2004 Apr;6(2):111-8
15191688
Clin Cancer Res. 2001 Jul;7(7):1923-31
11448905
J Clin Pathol. 2006 Apr;59(4):382-6
16467169
Cancer Res. 2002 Feb 1;62(3):632-5
11830510
Cancer. 2001 Jan 15;91(2):333-8
11180079
Am J Surg Pathol. 2001 May;25(5):579-86
11342768
CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27
8996076
World J Gastroenterol. 2003 Jul;9(7):1421-6
12854133
Clin Cancer Res. 2004 Jan 15;10(2):538-45
14760075
Ann Thorac Surg. 2006 Oct;82(4):1198-204
16996907
Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:95-114
12432912
Br J Surg. 1995 Jan;82(1):111-5
7881926
JAMA. 1999 Oct 6;282(13):1254-7
10517428
Lancet Oncol. 2001 Sep;2(9):544-51
11905709
Cancer Biol Ther. 2007 Oct;6(10):1569-75
18000398
Biochem Biophys Res Commun. 2003 Jul 11;306(4):887-97
12821125
Ann Surg. 2004 Jun;239(6):763-9; discussion 769-71
15166955
CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30
16514137
Int J Cancer. 1994 Jun 15;57(6):786-92
8206673
Mol Cancer Ther. 2003 Jan;2(1):1-7
12533667
Pancreatology. 2005;5(6):514-29
16110250
Oncogene. 1999 Dec 20;18(55):7908-16
10630643
Int J Pancreatol. 1999 Oct;26(2):69-76
10597402
Gastroenterology. 2002 Jun;122(7):1800-7
12055587